Kyprolis 60mg Injection (Carfilzomib) – Long Product Description

Kyprolis 60mg Injection (Carfilzomib) is a prescription anticancer medicine containing carfilzomib, a proteasome inhibitor used in the treatment of multiple myeloma. It is manufactured by Amgen and the specified pack size is 1 injection. Kyprolis is administered intravenously by a qualified healthcare professional and is generally used as part of a combination treatment regimen or, in specific circumstances, as a single agent.

Kyprolis 60mg Injection – Product Information

• Brand Name: Kyprolis
• Active Ingredient: Carfilzomib
• Strength: 60mg
• Dosage Form: Powder for solution for intravenous infusion
• Manufacturer: Amgen
• Pack Size: 1 Injection
• Route of Administration: Intravenous infusion
• Therapeutic Category: Antineoplastic / Proteasome Inhibitor
• Primary Use: Multiple Myeloma
• Prescription Status: Prescription medicine

What Is Kyprolis 60mg Injection?

Kyprolis 60mg Injection contains carfilzomib, a targeted anticancer medicine belonging to the class of drugs known as proteasome inhibitors. It is used for the treatment of multiple myeloma, a cancer of plasma cells in the bone marrow.

Carfilzomib works by inhibiting the proteasome, a protein-degrading system inside cells. Multiple myeloma cells can be particularly dependent on proteasome activity. Blocking this system can lead to accumulation of abnormal proteins and ultimately promote the death of malignant plasma cells.

Kyprolis is administered by intravenous infusion and requires careful monitoring by an oncology team.

What Is Kyprolis 60mg Used For?

Kyprolis is used to treat multiple myeloma in adults. Depending on the patient’s previous treatments and treatment history, carfilzomib may be prescribed:

• In combination with other anticancer medicines
• In combination with dexamethasone
• As part of a regimen containing lenalidomide and dexamethasone
• In combination with daratumumab and dexamethasone
• In combination with other approved multiple myeloma therapies
• As monotherapy in selected previously treated patients

The exact treatment regimen depends on the patient’s disease status, previous therapies, response to treatment, kidney and liver function, and overall health.

How Does Carfilzomib Work?

Carfilzomib is a selective proteasome inhibitor. Proteasomes are cellular structures responsible for breaking down proteins that cells no longer need or that have become damaged.

When carfilzomib inhibits the proteasome, proteins accumulate inside myeloma cells. This can disrupt normal cellular functions and promote programmed cell death, helping reduce the number of malignant plasma cells.

Because cancer cells can be especially dependent on the proteasome pathway, proteasome inhibition is an important treatment strategy in multiple myeloma.

Kyprolis 60mg Dosage and Administration

Kyprolis is administered intravenously as an infusion by a healthcare professional experienced in cancer treatment.

The dosage is not determined simply by the 60mg vial strength. The actual dose administered depends on the treatment regimen, patient’s body surface area, previous treatment, tolerance, and other clinical factors.

Different Kyprolis treatment schedules may use different starting doses and infusion schedules. Some regimens use carfilzomib on specific days of a treatment cycle rather than every day.

Patients may also receive fluids before and/or after treatment to reduce the risk of kidney-related complications and other infusion-associated problems.

Important: Kyprolis should never be self-administered. The oncology specialist determines the appropriate dose, infusion duration, treatment schedule, and any required dose modifications.

Kyprolis 60mg Side Effects

Like other anticancer medicines, Kyprolis can cause side effects. Commonly reported adverse effects may include:

• Fatigue
• Anemia
• Nausea
• Diarrhea
• Fever
• Shortness of breath
• Headache
• Cough
• Decreased appetite
• Low platelet count
• Low white blood cell count
• Muscle or joint pain
• Insomnia
• Swelling of the hands, feet, or legs

Some side effects may be serious and require immediate medical attention.

Serious Side Effects

Kyprolis has important warnings and precautions concerning potentially serious reactions, including:

• Heart failure and other cardiac complications
• High blood pressure
• Acute kidney injury
• Tumor lysis syndrome
• Severe infusion-related reactions
• Pulmonary complications
• Thrombotic microangiopathy
• Bleeding
• Low blood cell counts
• Liver toxicity
• Posterior reversible encephalopathy syndrome (PRES)
• Thromboembolic events

Seek urgent medical attention for severe breathing difficulty, chest pain, fainting, sudden swelling, severe headache, confusion, seizures, significant bleeding, or markedly reduced urine output.

Kyprolis Precautions

Before treatment with Kyprolis, inform the oncologist about all existing medical conditions and medicines being taken.

Special caution may be required in patients with:

• Heart disease
• High blood pressure
• Kidney impairment
• Liver problems
• A history of blood clots
• Previous serious reactions to cancer medicines
• Fluid imbalance
• Peripheral neuropathy
• Recent or planned surgery

Blood pressure, kidney function, liver function, blood counts, and other relevant laboratory parameters may need to be monitored during treatment.

Kyprolis and Heart Problems

Carfilzomib can cause serious cardiovascular complications in some patients. These may include heart failure, myocardial ischemia, arrhythmias, and hypertension.

Patients with existing cardiovascular disease should inform their healthcare provider before receiving Kyprolis. During treatment, report symptoms such as:

• New or worsening shortness of breath
• Chest discomfort
• Rapid heartbeat
• Sudden weight gain
• Swelling of the legs or ankles
• Unusual fatigue

Prompt evaluation is important if these symptoms develop.

Kyprolis and Kidney Function

Kidney-related adverse reactions can occur during carfilzomib therapy. Healthcare professionals may monitor serum creatinine and other indicators of kidney function.

Adequate hydration may be recommended before and after administration depending on the patient’s clinical condition. However, fluid administration must be individualized, particularly in patients who have heart failure or are at risk of fluid overload.

Kyprolis Pregnancy and Breastfeeding

Carfilzomib may cause fetal harm. Patients who are pregnant or planning pregnancy should discuss the risks with their healthcare professional before treatment.

Women who can become pregnant may need effective contraception during treatment and for an appropriate period after the final dose, according to the prescribing information and medical advice.

Patients should also discuss breastfeeding with their healthcare provider before starting Kyprolis. Breastfeeding may need to be avoided during treatment and for the recommended period afterward.

Kyprolis Contraindications

Kyprolis should not be administered to patients with a known serious hypersensitivity to carfilzomib or any of the components of the formulation.

The treating oncologist should carefully evaluate patients with significant cardiovascular, renal, hepatic, or other serious medical conditions before treatment.

Kyprolis Drug Interactions

Tell your healthcare provider about all prescription medicines, over-the-counter medicines, vitamins, and supplements you use.

Because Kyprolis is generally administered as part of a multiple myeloma treatment regimen, it may be combined with medicines such as dexamethasone, lenalidomide, daratumumab, or other anticancer therapies depending on the approved regimen.

The oncology team should review the complete medication list before treatment to minimize potential interactions and overlapping toxicities.

Kyprolis 60mg Storage

Kyprolis is a healthcare-administered injectable product. The unopened vial should be stored according to the manufacturer’s recommended storage conditions and protected from inappropriate temperature and light exposure.

After reconstitution, handling and storage must follow the product’s professional preparation instructions. Only trained healthcare professionals should prepare and administer Kyprolis.

Kyprolis 60mg Pack Size

Kyprolis 60mg Injection – Pack Size: 1 Injection

The product is supplied as a single 60mg vial intended for preparation and intravenous administration by qualified healthcare professionals.

Kyprolis 60mg Manufacturer

Manufacturer: Amgen

Amgen is a biotechnology and pharmaceutical company involved in the development and manufacture of medicines for serious diseases, including oncology products.

Kyprolis 60mg Price in Pakistan

The price of Kyprolis 60mg Injection in Pakistan may vary depending on availability, supplier, import status, exchange rates, and pharmacy or distributor pricing.

For the latest Kyprolis 60mg price and availability in Pakistan, customers can contact MedicineWalyDost.com before placing an order.

Why Buy Kyprolis 60mg Injection from MedicineWalyDost.com?

If you are searching for Kyprolis 60mg Injection (Carfilzomib) in Pakistan, MedicineWalyDost.com can help you check current availability and ordering information.

Because Kyprolis is a specialized prescription oncology medicine, it should be purchased from a reliable source and administered only under the supervision of a qualified oncology professional.

Contact MedicineWalyDost.com to check the latest Kyprolis 60mg availability, price, and delivery options in Pakistan. Order your prescribed Kyprolis injection with confidence and appropriate medical guidance.

Frequently Asked Questions About Kyprolis 60mg

What is Kyprolis 60mg Injection?

Kyprolis 60mg Injection contains carfilzomib, a proteasome inhibitor used to treat adults with multiple myeloma.

What is Kyprolis used for?

Kyprolis is used in the treatment of multiple myeloma, usually as part of a combination regimen and, in certain circumstances, as monotherapy.

Who manufactures Kyprolis 60mg?

Kyprolis is manufactured by Amgen.

How many injections are in one Kyprolis 60mg pack?

The specified pack size is 1 injection/vial containing 60mg of carfilzomib.

How is Kyprolis administered?

Kyprolis is given as an intravenous infusion by a qualified healthcare professional. It should not be injected or administered by patients themselves.

Is Kyprolis a chemotherapy medicine?

Kyprolis is an anticancer medicine but belongs specifically to the proteasome inhibitor class. It works differently from many traditional cytotoxic chemotherapy medicines.

What are the common side effects of Kyprolis?

Common side effects can include fatigue, anemia, nausea, diarrhea, fever, shortness of breath, headache, cough, decreased appetite, and changes in blood cell counts.

Can Kyprolis affect the heart?

Yes. Carfilzomib can cause serious cardiovascular complications, including heart failure and high blood pressure. Patients should be monitored closely during treatment.

Can Kyprolis affect the kidneys?

Yes. Kidney complications can occur, and kidney function may be monitored before and during treatment.

Is Kyprolis available without a prescription?

No. Kyprolis is a specialized prescription oncology medicine and should only be used under the supervision of an experienced healthcare professional.

Key Product Summary

Kyprolis 60mg Injection (Carfilzomib) is a prescription proteasome inhibitor manufactured by Amgen and supplied in a pack size of 1 injection/vial. It is used for the treatment of multiple myeloma in adults according to an appropriate oncology treatment regimen. Because carfilzomib can cause significant cardiovascular, renal, hematologic, infusion-related, and other adverse effects, treatment requires careful medical supervision and monitoring.

Important: This product description is intended for general informational and SEO purposes and does not replace the advice of an oncologist or other qualified healthcare professional. Kyprolis should be administered only according to the prescribed treatment regimen.Buy Kyprolis 60mg Injection (Carfilzomib) by Amgen for multiple myeloma treatment. Check Kyprolis 60mg price and availability in Pakistan at MedicineWalyDost.com.